A clinical trial of low dose methotrexate therapy in patients with rheumatoid arthritis

Japanese Journal of Clinical Immunology

Volumn 28, Issue 6, 2005, Pages 389-397

  Nagaoka, Shouhei ^a   Nakamura, Mitsuyuki ^a   Senuma, Akiko ^a   Sekiguchi, Akiko ^a  

^a Yokohama Minami Kyosai Hospital   (Japan)

Author keywords

ACR; Methotrexate; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT; METHOTREXATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG MONITORING; FEMALE; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 33644839226     PISSN: 09114300     EISSN: 13497413     Source Type: Journal    
DOI: 10.2177/jsci.28.389     Document Type: Article

References (37)

1. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines: Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. 46: 328–346, 2002.
2. Anderson, P. A., et al.: Weekly pulse methotrexate in rheumatoid arthritis: Clinical and immunologic effects in a randomized double-blind study. Ann. Intern.Med. 103: 489–496, 1985.
3. Strand, V., et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch. Intern. Med. 159: 2542–2550, 1999.
4. Weinblatt, M. E., et al.: Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy. J. Rheumatol. 25: 238–242, 1998.
5. Choi, H. K., et al.: Methotrexate and mortality in patients with rheumatoid arthritis; A prospective study. Lancet 359: 1173–1177, 2002.
6. Klareskog, L., et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363: 675–681, 2004.
7. St. Clair, E. W., et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum. 50: 3432–3443, 2004.
8. Lipsky, P. E., et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis.N. Engl. J. Med. 343: 1594–1602, 2000.
9. Bathon, J. M., et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. 343: 1586–1593, 2000.
10. Cohen, S., et al.: Two-year,blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Arthritis Rheum. 44: 1984–1992, 2001.
11. Alarcon, G. S., et al.: Methotrexate in rheumatoid arthritis: toxic effects as the major factor in limiting long-term treatment. Arthritis Rheum. 32: 671–676, 1989.
12. Hanrahan, P. S., et al.: Prospective long-term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity,efficacy and radiological progression. Br. J. Rheumatol. 28: 147–153, 1989.
13. Sany, J., et al.: Treatment of rheumatoid arthritis with methotrexate: a prospective open longterm study of 191 cases. J. Rheumatol. 18: 1323–1327, 1991.
14. Weinblatt, M. E., et al.: Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis: 84-month update. Arthritis Rheum. 35: 129–137, 1992.
15. Wolfe, F., et al.: The effect of age on methotrexate efficacy and toxicity. J. Rheumatol. 18: 973–977, 1991.
16. Poole, P., et al.: Methotrexate in older patients with rheumatoid arthritis. Br. J. Rheumatol. 31: 860, 1992.
17. Toloza, S. M. A., et al.: Methotrexate and leflunomide: use in the treatment of rheumatoid arthritis and other rheumatic disorders. Koopman, W. J. & Moreland, L. W., eds. Arthritis and Allied Conditions, 15th ed., Williams and Wilkins, Baltimore, 705–738, 2005.
18. Vandenbroucke, J. P., et al.: Survival and cause of death in rheumatoid arthritis: a 25 year prospective follow-up. J. Rheumatol. 11: 158–161, 1984.
19. Wolfe, F., et al.: The mortality of rheumatoid arthritis. Arthritis Rheum. 37: 481–494, 1994.
20. Kremer, J. M., et al.: Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum. 37: 316–328, 1994.
21. Clegg, D. O., et al.: Acute, reversible hepatic failure associated with methotrexate treatment of rheumatoid arthritis. J. Rheumatol. 16: 1123–1126, 1989.
22. Hakim, N. S., et al.: Methotrexate-induced hepatic necrosis requiring liver transplantation in a patient with rheumatoid arthritis. Int. Surv. 83: 224–225, 1998.
23. Erickson, A. R., et al.: Usefulness of the American College of Rheumatology recommendations for liver biopsy in methotrexate-treated rheumatoid arthritis patients. Arthritis Rheum. 38: 1115–1119, 1995.
24. Kent, P. D., et al.: Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis. J. Rheumatol. 31: 1727–1731, 2004.
25. Gutierrez-Urena, S., et al.: Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis. Arthritis Rheum. 39: 272–276, 1996.
26. Weinblatt, M. E., et al.: Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum. 32: 1592–1596, 1989.
27. Grove, M. L., et al.: Adverse reactions to disease-modifying antirheumatic drugs in clinical practice. Q. J. Med. 94: 309–319, 2001.
28. Carroll, G. J., et al.: Incidence, prevalence and possible risk factors for pneumonitis in patients with rheumatoid arthritis receiving methotrexate. J. Rheumatol. 21: 51–54, 1994.
29. Bartram, S. A.: Experience with methotrexate-associated pneumonitis in northeastern England. Arthritis Rheum. 41: 1327–1328, 1998.
30. Kremer, J. M., et al.: Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 40: 1829–1837, 1997.
31. Imokawa, S., et al.: Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur. Respir. J. 15: 373–381, 2000.
32. Alarcon, G. S., et al.: Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-lung study group. Ann. Intern. Med. 127: 356–364, 1997.
33. Searles, G., et al.: Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J. Rheumatol. 14: 1164–1171, 1987.
34. Saravanan, V., et al.: Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology 43: 143–147, 2004.
35. Baum, J.: Infection in rheumatoid arthritis. Arthritis Rheum. 14: 135–137, 1971.
36. Wilke, W. S., et al.: Incidence of toxicity in patients wiyh rheumatoid arthritis treated methotrexate. Rheumatology 9: 134–144, 1986.
37. Preston, S. J., et al.: Methotrexate osteopathy in rheumatic disease. Ann. Rheum. Dis. 52: 582–585, 1993.